NEW YORK (GenomeWeb) – Foundation Medicine said today that the US Food and Drug Administration has granted Breakthrough Device designation to a new liquid biopsy assay the firm is developing, an expanded version of its existing FoundationACT assay.

Under the Breakthrough Device program, an expansion of the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval.